Overview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...

May 10, 2024 · Jessica Langbaum Banner Alzheimer's Institute; Eric M. Reiman Arizona Alzheimer's Consortium; Posted: 10 May 2024 We commend Fortea and colleagues for their analyses examining biomarker and clinical changes in a large number of cognitively impaired and unimpaired persons from NACC, Alfa plus, A4 trial, OASIS, ADNI, and WRAP.

6 days ago · Joseph Arboleda-Velasquez on ApoE3 Christchurch Clings Tightly to Tau, Averting Tangles 01 Feb 2025; Seong Kang on ApoE3 Christchurch Clings Tightly to Tau, Averting Tangles 01 Feb 2025; Stephen Salloway on Leqembi Maintenance Dosing Approved in the U.S. 31 Jan 2025; Teresa Gomez-Isla on Leqembi Maintenance Dosing Approved in the U.S. 31 Jan 2025; Julia TCW on A neurodegenerative cellular ...

15 Mar 2024. A record 4,700 people from 70 countries attended the 18th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 5 to 9 in Lisbon, Portugal.

Overview. Name: Remternetug Synonyms: LY3372993, N3pG-Abeta mAb Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Remternetug, previously LY3372993, is an investigational monoclonal antibody. Lilly's development pipeline lists it as an N3pG-Aβ mAb, suggesting ...

Jan 10, 2025 · Overview. Name: Trontinemab Synonyms: RO7126209, RG6102 , Brain shuttle gantenerumab Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1/2) Company: Hoffmann-La Roche Background. RO7126209 is a new version of the anti-amyloid monoclonal antibody gantenerumab, engineered to more easily cross the blood ...

Dec 16, 2022 · Overview. Name: TB006 Therapy Type: Immunotherapy (passive) Target Type: Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1) Company: TrueBinding, Inc. Background. This humanized monoclonal antibody targets galactose-specific lectin (galectin) 3, a β-galactosidase-binding protein involved in macrophage activation and antimicrobial immune responses.

Apr 18, 2022 · Overview. Name: Simufilam Synonyms: PTI-125, sumifilam Chemical Name: 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one Therapy Type: Small Molecule Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Discontinued) Company: Cassava Sciences Background. Simufilam binds to filamin, a ubiquitous scaffolding protein and regulator of the actin ...

Overview. Name: Varoglutamstat Synonyms: PQ912 Chemical Name: (S)-1-(1H-benzo[d]imidazol-5-yl)-5-(4- propoxyphenyl)imidazolidin-2-one Therapy Type: Small Molecule Target Type: Amyloid-Related , Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Discontinued) Company: Probiodrug AG, Vivoryon Therapeutics N.V. Background. PQ912 is an inhibitor of glutaminyl ...

Oct 9, 2023 · Papers. Gauthier S, Molinuevo JL.Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 2012 Oct 27; PubMed.; Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.